文献速递新发突发、热带与寄生虫病

靶向CyRPA、RH5与MSP-119的抗体组合高效中和印度及非洲恶性疟原虫临床分离株

Antibody Combinations Targeting the Essential Antigens CyRPA, RH5, and MSP-119 Potently Neutralize Plasmodium falciparum Clinical Isolates From India and Africa.
PubMed 文献 · J Infect Dis · 2021-01-01

研究评估了不同抗体单独及联合使用对实验室适应株和临床分离株的疟原虫中和活性。临床分离株来自印度中部和莫桑比克,并表征其入侵特性及入侵配体的遗传多样性。在25种三抗体组合中,MSP-Fu+CyRPA+RH5组合对经最小体外培养、特性各异的恶性疟原虫临床分离株表现出最大中和效果。

要点

  • MSP-Fu+CyRPA+RH5三抗体组合对恶性疟原虫临床分离株中和效果最强。
  • 临床分离株来自印度中部和莫桑比克,经最小体外培养。
  • 该组合为组合式恶性疟原虫红内期疫苗提供概念验证。

核心结论

  • MSP-Fu+CyRPA+RH5抗体组合对恶性疟原虫克隆和临床分离株均表现出高度稳健的寄生虫中和作用,支持其作为有前景的候选抗原并为组合式红内期疟疾疫苗开发提供概念验证。

研究设计与样本

  • 研究评估不同抗体单独及联合使用对实验室适应克隆和临床分离株的寄生虫中和活性。
  • 临床分离株采集自印度中部和莫桑比克非洲地区,并表征其入侵特性及入侵配体的遗传多样性。
  • 共评估25种三抗体组合。

主要发现

  • 在25种三抗体组合中,MSP-Fu+CyRPA+RH5组合对经最小体外培养、特性各异的恶性疟原虫临床分离株表现出最大寄生虫中和效果。

临床怎么用

  • 该抗体组合可作为组合式恶性疟原虫红内期疟疾疫苗的候选抗原组合进一步开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Targeting multiple key antigens that mediate distinct Plasmodium falciparum erythrocyte invasion pathways is an attractive approach for the development of blood-stage malaria vaccines. However, the challenge is to identify antigen cocktails that elicit potent strain-transcending parasite-neutralizing antibodies efficacious at low immunoglobulin G concentrations feasible to achieve through vaccination. Previous reports have screened inhibitory antibodies primarily against well adapted laboratory parasite clones. However, validation of the parasite-neutralizing efficacy against clinical isolates with minimal in vitro cultivation is equally significant to better ascertain their prospective in vivo potency. METHODS: We evaluated the parasite-neutralizing activity of different antibodies individually and in combinations against laboratory adapted clones and clinical isolates. Clinical isolates were collected from Central India and Mozambique, Africa, and characterized for their invasion properties and genetic diversity of invasion ligands. RESULTS: In our portfolio, we evaluated 25 triple antibody combinations and identified the MSP-Fu+CyRPA+RH5 antibody combination to elicit maximal parasite neutralization against P. falciparum clinical isolates with variable properties that underwent minimal in vitro cultivation. CONCLUSIONS: The MSP-Fu+CyRPA+RH5 combination exhibited highly robust parasite neutralization against P. falciparum clones and clinical isolates, thus substantiating them as promising candidate antigens and establishing a proof of principle for the development of a combinatorial P. falciparum blood-stage malaria vaccine.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Singh H, Mian SY, Pandey AK, et al. Antibody Combinations Targeting the Essential Antigens CyRPA, RH5, and MSP-119 Potently Neutralize Plasmodium falciparum Clinical Isolates From India and Africa. J Infect Dis. 2021. PMID: 32989463. doi:10.1093/infdis/jiaa608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。